Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease
Public ClinicalTrials.gov record NCT03992066. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b, Randomized, Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease
Study identification
- NCT ID
- NCT03992066
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Akebia Therapeutics
- Industry
- Enrollment
- 46 participants
Conditions and interventions
Interventions
- Vadadustat Drug
- Darbepoetin alfa Drug
- Epoetin alfa Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 27, 2019
- Primary completion
- May 4, 2020
- Completion
- Jul 14, 2020
- Last update posted
- Sep 15, 2020
2019 – 2020
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Escondido | California | 92025 | — |
| Research Site | Denver | Colorado | 80230 | — |
| Research Site | Fort Lauderdale | Florida | 33308 | — |
| Research Site | Miami | Florida | 33133 | — |
| Research Site | Miami Beach | Florida | 33140 | — |
| Research Site | Orlando | Florida | 32809 | — |
| Research Site | Kansas City | Missouri | 64111 | — |
| Research Site | Midwest City | Oklahoma | 73130 | — |
| Research Site | Providence | Rhode Island | 02903 | — |
| Research Site | Chattanooga | Tennessee | 37404 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03992066, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 15, 2020 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03992066 live on ClinicalTrials.gov.